-
Mashup Score: 101Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better? - 1 month(s) ago
Our assessment of cancer immunotherapies (CIT) randomized controlled trials (RCTs) published over the last two years in major journals (Appendix 2) reveals that knowledge of toxicities is still hindered by practices in the reporting and analysis of safety data.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047] - 1 month(s) ago
Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 99Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better? - 1 month(s) ago
Our assessment of cancer immunotherapies (CIT) randomized controlled trials (RCTs) published over the last two years in major journals (Appendix 2) reveals that knowledge of toxicities is still hindered by practices in the reporting and analysis of safety data.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Oncogenic extrachromosomal DNA identification using whole-genome sequencing from formalin-fixed glioblastomas - 1 month(s) ago
Glioblastoma, an area of urgent unmet clinical need, is the most common intrinsic brain cancer and frequently contains extrachromosomal DNA (ecDNA). EcDNA is increasingly recognized as a driver of cancer evolution and a mediator of therapy resistance1,2. Recent studies have implicated ecDNA as a prognostic marker across many cancer types, and a driver of glioblastoma, with emerging clinical trials aiming to leverage knowledge of ecDNA status or therapeutically target ecDNA directly3.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 99Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better? - 1 month(s) ago
Our assessment of cancer immunotherapies (CIT) randomized controlled trials (RCTs) published over the last two years in major journals (Appendix 2) reveals that knowledge of toxicities is still hindered by practices in the reporting and analysis of safety data.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial - 1 month(s) ago
Sacituzumab govitecan (SG), a novel antibody-drug conjugate targeting Trop2, is approved for pre-treated metastatic triple negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG (NCT04230109), and report primary results
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11New ADCs bring new questions in EGFR NSCLC and beyond - 2 month(s) ago
Antibody drug conjugates (ADCs) represent one of the fastest growing therapeutic drug classes in solid tumor oncology. The ability to combine highly potent payload moieties with monoclonal antibodies selective for tumor specific antigens has shifted our approach in treating patients with multiple different tumor types, including non-small cell lung cancer (NSCLC). Currently three ADCs in NSCLC have received accelerated approval or breakthrough therapy designation from the FDA, including trastuzumab deruxtecan (T-DXd) for HER2-mutated NSCLC, telisotuzumab vedotin (Teliso-V) for NSCLC with MET overexpression, and patritumab deruxtecan (HER3-DXd) for EGFR-mutated NSCLC.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 393ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma - 2 month(s) ago
The following ESMO Clinical Practice Guideline (CPG) has been recently updated with new treatment recommendations and an updated algorithm for managing treatment-naive advanced or metastatic urothelial carcinoma (stage IV): Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.1
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
New @myESMO guidlines for advanced bladder cancer @Annals_Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available https://t.co/wx2AD4eEGn https://t.co/acDNKSPHzp
-
-
Mashup Score: 156ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia - 2 month(s) ago
The following ESMO Clinical Practice Guideline (CPG) has been recently updated with new treatment recommendations:
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma - 2 month(s) ago
In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
Important letter to the editor @Annals_Oncology on immune related adverse events. Do we know what is truly immune related? Need to capture all-cause AEs for discovery purposes. And we desperately need harmonization of CTCAE to align terms. @myESMO https://t.co/MaNxM611dM